BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10024837)

  • 1. [Conversion from oral ACE inhibitor to intravenous quinaprilat administration in mild to moderate essential hypertension].
    Schmidt BM; Smilde J; Oldenbroek C; Wehling M
    Med Klin (Munich); 1998 Dec; 93(12):701-6. PubMed ID: 10024837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model.
    Whelton A; McCormick L; Wombolt D; Goldstein R; Canter D
    Eur Heart J; 1997 Jan; 18(1):140-7. PubMed ID: 9049526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
    Breslin E; Posvar E; Neub M; Trenk D; Jahnchen E
    J Clin Pharmacol; 1996 May; 36(5):414-21. PubMed ID: 8739020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
    Mitrovic V; Mudra H; Bonzel T; Schmidt W; Schlepper M
    Z Kardiol; 1996 Nov; 85(11):828-38. PubMed ID: 9064945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of hypertension in older patients.
    Schnaper HW
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S56-61. PubMed ID: 1691408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril.
    Frishman WH; Greenberg S
    Am J Hypertens; 1991 Oct; 4(10 Pt 1):827-31. PubMed ID: 1747216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative study of the effects of lisinopril and quinapril administered once a day in essential hypertension].
    De Cesaris R; Ranieri G; Andriani A; Chiarappa R
    Minerva Med; 1990; 81(7-8):541-6. PubMed ID: 2166253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
    Culy CR; Jarvis B
    Drugs; 2002; 62(2):339-85. PubMed ID: 11817979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
    Sedman AJ; Posvar E
    Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinapril: a new second-generation ACE inhibitor.
    Cetnarowski-Cropp AB
    DICP; 1991 May; 25(5):499-504. PubMed ID: 2068835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany.
    Nussberger J; Fleck E; Bahrmann H; Delius W; Schultheiss HP; Brunner HR
    Eur Heart J; 1994 Dec; 15 Suppl D():113-22. PubMed ID: 7713100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study.
    Miller MA; Texter M; Gmerek A; Robbins J; Shurzinske L; Canter D
    Cardiovasc Drugs Ther; 1994 Apr; 8(2):271-5. PubMed ID: 7918140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of quinapril in the treatment of mild to moderate essential hypertension.
    Frishman WH
    Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII19-25. PubMed ID: 2189617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension.
    Romero R; Castellote E; Ocón J; Wagner B
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):114-8. PubMed ID: 7564350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of mild to moderate hypertension with ACE inhibitors.
    Taylor SH
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S24-8. PubMed ID: 1691403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril.
    Palatini P; Racioppa A; Raule G; Zaninotto M; Penzo M; Pessina AC
    Clin Pharmacol Ther; 1992 Oct; 52(4):378-83. PubMed ID: 1330398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinapril versus atenolol in the treatment of mild to moderate essential hypertension.
    Bahena JH; Estrella ME; Muñoz M
    Clin Ther; 1992; 14(4):527-36. PubMed ID: 1525787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension.
    Taylor SH
    Angiology; 1989 Apr; 40(4 Pt 2):382-8. PubMed ID: 2539763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.
    Elliott HL; Macdonald NJ; Meredith PA; Reid JL
    Clin Pharmacol Ther; 1992 Mar; 51(3):260-5. PubMed ID: 1312002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.